JangoBio

Executive Summary

JangoBio is a preclinical-stage biotechnology company based in Cambridge, MA, founded in 2021 to address age-related hormonal decline. The company's core thesis is that the loss of functional ovarian and testicular cells (hypogonadism) drives many aging processes and age-related diseases. Rather than simply supplementing hormones, JangoBio aims to restore the body's natural hormone production by regenerating or replacing these critical cell populations, potentially offering a more physiologic and durable solution for conditions such as menopause and andropause. The company's approach falls within the cell and gene therapy space, leveraging advances in regenerative medicine to target the root cause of hormonal aging. As a private company with no disclosed funding or valuation, JangoBio is in an early stage of development, but its focus on a large and underserved patient population positions it for potential significant impact if its technology proves successful.

Upcoming Catalysts (preview)

• 2026 Q4Series A Financing60% success
• 2027 Q1Preclinical Proof-of-Concept Data Release50% success
• 2027 Q2IND-Enabling Studies Initiation40% success